Core Viewpoint - Beijing Tongrentang has taken immediate action against a product labeled as "99% high-purity Antarctic krill oil," which is suspected of false ingredient labeling, by halting its distribution and initiating legal proceedings against the involved company [1][4]. Group 1: Company Actions - The company has ordered its subsidiary, Sichuan Tongrentang Health Pharmaceutical Co., Ltd., to stop the distribution of the questionable product and is conducting a full traceability check [1]. - Legal action has been initiated against the involved parties to protect consumer rights and the company's brand image [1]. Group 2: Product Details - A recent consumer protection investigation revealed that the krill oil product, which claimed to contain a high phospholipid content, was found to have zero phospholipid content in actual testing [4][5]. - The product was marketed with claims of high content and imported raw materials, but the actual composition raises significant concerns about its authenticity [4][6]. Group 3: Industry Context - Antarctic krill oil is known for its phospholipid content, which is essential for its emulsifying properties and absorption; the absence of phospholipids in the product contradicts its fundamental definition [6]. - The product in question is considered a "private label" item of Beijing Tongrentang, as it is produced by Anhui Habao Pharmaceutical Co., Ltd. and distributed by its subsidiary [6].

近日，上海市消保委称一款标注"安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司经销"的"99%高纯南极磷虾油"产品，相关成分涉嫌虚 假标注。为此，上海市消保委已约谈生产厂家及产品经销商。 12月15日，北京同仁堂健康药业股份有限公司发布声明称，针对上述情况，公司立即责令四川健康药业停止经销该产品，并对涉事产品开展全流程核查与追 溯。北京同仁堂健康药业还称，这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法程序，对涉事企业进行起诉。 12月15日晚间，第一财经记者在京东平台上搜索"同仁堂磷虾油"，依然发现了这款涉嫌造假的北京同仁堂（四川）健康药业有限公司的"朕皇"商标磷虾油产 品，尚未下架。一瓶售价为21元。 不过，12月15日晚间，第一财经记者在京东平台上搜索"同仁堂磷虾油"，依然发现了这款涉嫌造假的北京同仁堂（四川）健康药业有限公司的"朕皇"商标磷 虾油产品，尚未下架。在宣传网页上仍写着"智利进口原料"、"99%高纯度"，其磷脂标识值为43%。点击购买页面也仍能购买该产品，一瓶售价为21元。 上海大邦律师事务所合伙人游云庭对第一财经记者表示："北京同仁堂对孙公司的起诉，更像 ...

12月15日，北京同仁堂健康药业股份有限公司发布声明： 近日，有媒体报道一款标注"安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称'四川健康药业'）经销"的"99%高纯南极磷虾 油"产品，相关成分涉嫌虚假标注。 针对上述情况，我公司立即责令四川健康药业停止经销该产品，并对涉事产品开展全流程核查与追溯。这款产品未经授权擅自突出使用"北京同仁堂"字 样，涉嫌违法，我们已启动司法程序，对涉事企业进行起诉，以求维护广大消费者和企业的合法权益。 同仁堂始终把产品质量与消费者健康放在首位。我们郑重承诺，公司将进一步加强管理，与广大消费者和相关各方一道，坚决抵制任何影响消费者健康、 企业品牌形象与各方合法权益的行为。 我们愿诚恳接受社会各界的监督与指导，共同维护健康有序的市场环境。在此，也郑重提醒广大消费者：请务必通过正规渠道购买"北京同仁堂"产品，并 认准"同仁堂"双龙图案商标，避免权益受损。 早前报道 最近 南极磷虾油成为健康圈的"香饽饽" 商家普遍宣传它能改善大脑功能 守护心血管、增强免疫力 号称深海馈赠的"黄金营养液" 那么"南极磷虾油里有什么？" "真的有用吗？" 南极磷虾。图源：视觉中国 ...

12月11日，智通财经记者从上海市消保委获悉，近日，其托中国水产科学研究院东海水产研究所，对市 面上热销的15款国内外南极磷虾油产品开展了检测和调查，重点关注磷脂、虾青素、EPA、DHA含量及 价格（销售价格可能因销售活动等因素有所波动）。其中，一款标称"北京同仁堂99%高纯南极磷虾 油"的产品，磷脂标识值为43%，实测为0。上海市消保委透露，将于近日约谈该产品的生产企业安徽哈 博药业有限公司和经销商北京同仁堂（四川）健康药业有限公司，要求其对产品的真实情况做出解释。 目前，尚无针对南极磷虾油产品质量评价的专门标准，各核心成分的测定均参考了现行国家或行业标准 方法，具体如下： 磷脂含量检测依据： GB/T 5537-2008《粮油检验 磷脂含量的测定》（第一法）； 虾青素含量检测依据： SC/T 3053-2019《水产品及其制品中虾青素含量的测定 高效液相色谱法》； 智通财经记者 吕新文 高级记者 邹娟 12月15日，北京同仁堂通过微信公众号"同仁堂健康会员"发布声明称，有媒体报道一款标注"安徽哈博 药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称'四川健康药业'）经销"的"99% 高纯南极磷 ...

Investment Rating - The report indicates a strong growth potential for the bird's nest peptide industry, with a projected market expansion from 2.17 billion CNY in 2022 to 16 billion CNY by 2029, reflecting a compound annual growth rate (CAGR) of 35.47% [8][9]. Core Insights - The bird's nest peptide industry is characterized by high biological activity and absorption, driven by technological innovations and a focus on modern biotechnology to enhance product efficacy [5][6]. - The market is evolving from research exploration to industrialization, with significant growth observed since 2018, particularly in product forms and applications [7]. - Demand is primarily driven by high-income consumers seeking precise nutrition and health benefits, with brands employing multi-channel strategies to enhance market penetration [11]. Market Background - Bird's nest peptides are derived from edible bird's nests through hydrolysis, resulting in small molecular peptides with high bioactivity [5]. - The industry has transitioned from academic research to commercialization, with key technological advancements facilitating this shift [7]. Market Status - The market size is expected to grow significantly, with a CAGR of 28.62% from 2022 to 2024, and an anticipated acceleration to 35.47% from 2025 to 2029 [8][9]. - Supply is characterized by high technical barriers and concentration among leading brands, with significant reliance on patented processes for production [10]. - Demand is robust, driven by middle to high-income consumers, with brands leveraging both online and offline channels for effective market reach [11]. Market Competition - The competitive landscape is defined by leading companies like Zheng Dian Yan Wo and Yan Zhi Wu, which have established significant barriers through raw material control and proprietary technologies [13]. - The competition has evolved from product-based to a comprehensive evaluation of supply chain control, technological innovation, and multi-scenario applications [13]. - The report highlights ten recommended brands, each with unique strengths in product quality, technological innovation, and market positioning [14][15][16]. Development Trends - The industry is moving towards technological, functional, and standardized advancements, with a focus on cross-industry integration [17]. - Companies are increasingly investing in research to validate health benefits scientifically, shifting from concept marketing to evidence-based claims [17]. - The report emphasizes the importance of comprehensive capabilities in research, technology barriers, and innovative applications for future market leadership [17].

同仁堂在声明中表示，这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，公司已启动司法 程序，对涉事企业进行起诉。 12月15日，"同仁堂健康会员"微信公众号发布声明称，有媒体报道一款标注"安徽哈博药业有限公司生 产、北京同仁堂（四川）健康药业有限公司经销"的"99%高纯南极磷虾油"产品，相关成分涉嫌虚假标 注。针对上述情况，公司立即责令四川健康药业停止经销该产品，并对涉事产品开展全流程核查与追 溯。 （原标题：同仁堂声明：已起诉！） ...

12月15日，"同仁堂健康会员"微信公众号发布声明称， 近日，有媒体报道一款标注"安徽哈博药业有限公司生产、北京同仁堂（四川）健 康药业有限公司（以下简称'四川健康药业'）经销"的"99%高纯南极磷虾油"产品，相关成分涉嫌虚假标注。针对上述情况，公司立即责令 四川健康药业停止经销该产品，并对涉事产品开展全流程核查与追溯。 下载财联社APP获取更多资讯 准确 快速 权威 专业 7x24h电报 头条新闻 VIP资讯 实时盯盘 上述声明称，这款产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，同仁堂已启动司法程序，对涉事企业进行起诉，以求维护广大 消费者和企业的合法权益。 同仁堂表示，公司将进一步加强管理，与广大消费者和相关各方一道，坚决抵制任何影响消费者健康、企业品牌形象与各方合法权益的行 为。同时，也郑重提醒广大消费者：请务必通过正规渠道购买"北京同仁堂"产品，并认准"同仁堂"双龙图案商标，避免权益受损。 ...

Macro Dynamics - The Ministry of Commerce and five other departments issued the "Action Plan for Promoting High-Quality Development of Service Outsourcing," aiming to cultivate a group of internationally competitive leading service outsourcing enterprises by 2030 [2] - The plan emphasizes the digitalization, intelligence, greening, and integration of service outsourcing, with a significant increase in employment [2] Steel Industry - As of early December, the steel inventory of key steel enterprises reached 14.75 million tons, a year-to-date increase of 19.2% [3] Fixed Asset Investment - From January to November, national fixed asset investment (excluding rural households) totaled 4.44035 trillion yuan, a year-on-year decrease of 2.6% [4] Financial Institutions - CITIC Bank clarified that it has never cooperated with "KOO Wallet" and warned against fraudulent activities using its name [5] - ICBC announced adjustments to its management of personal precious metal trading business, urging clients to withdraw funds from accounts with no positions or debts [6] Market Data - On December 15, A-shares saw a collective decline, with the Shanghai Composite Index down 0.55% and the ChiNext Index down 1.77%, with a total market turnover of approximately 1.773439 trillion yuan [8] - Hong Kong stocks also fell, with the Hang Seng Index down 1.34% and the Hang Seng Tech Index down 2.48% [9] Company Dynamics - Muxi Co., Ltd. announced that its stock will be listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on December 17, 2025, and will be classified as a growth tier company due to its current unprofitability [10] - Cambrian Technology plans to use 2.778 billion yuan from its capital reserve to offset accumulated losses [11] - Unisoc's board approved the establishment of a Central Research Institute focusing on AI chip architecture and other advanced technologies [12] - Tongrentang announced legal action against a company for unauthorized use of its name on a product with allegedly false labeling [13] - Baina Qiancheng is planning a major asset restructuring and will suspend its stock trading starting December 16, 2025 [14]

Core Viewpoint - Tong Ren Tang Health has issued a statement regarding a product labeled as "99% high-purity Antarctic krill oil," produced by Anhui Habao Pharmaceutical Co., Ltd. and distributed by Beijing Tong Ren Tang (Sichuan) Health Pharmaceutical Co., Ltd., which allegedly contains false ingredient labeling [1][2] Group 1 - The company has ordered Sichuan Health Pharmaceutical to cease distribution of the product and has initiated a full-process investigation and traceability of the involved product [1] - The product was found to have used the "Beijing Tong Ren Tang" name without authorization, which is considered illegal, prompting the company to initiate legal proceedings against the involved enterprises to protect consumer and corporate rights [2] - The company has committed to strengthening management and collaborating with consumers and relevant parties to resist any actions that could harm consumer health, brand image, and legal rights [2]

同时，声明表示，该产品未经授权擅自突出使用"北京同仁堂"字样，涉嫌违法，同仁堂已启动司法程 序，对涉事企业进行起诉，以求维护广大消费者和企业的合法权益。 北京商报讯（记者 王寅浩 宋雨盈）12月15日，"同仁堂健康会员"公众号发布声明称，近日，有媒体报 道一款标注"安徽哈博药业有限公司生产、北京同仁堂（四川）健康药业有限公司（以下简称'四川健康 药业'）经销"的"99%高纯南极磷虾油"产品，相关成分涉嫌虚假标注。针对上述情况，公司立即责令四 川健康药业停止经销该产品，并对涉事产品开展全流程核查与追溯。 ...